secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001493152-25-022505
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mangoceuticals clarifies GLP-1 programs: no direct contracts with Eli Lilly or Novo Nordisk
--------------------------------------------------------------------------------

- MangoRx Direct and PeachesRx Direct can prescribe branded GLP-1s (Zepbound, Wegovy) via third-party provider.
- Company has no direct contractual relationship with Eli Lilly or Novo Nordisk; access is through an independent provider.
- Programs launched Nov 13, 2025 at $99/month; medication cost and fulfillment separate.
- Clarification follows earlier press release that may have implied direct partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315225022505/0001493152-25-022505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315225022505/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer